Analyzing Masimo (NASDAQ:MASI) & NeurAxis (NASDAQ:NRXS)

Masimo (NASDAQ:MASI) and NeurAxis (NASDAQ:NRXS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Risk and Volatility

Masimo has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 4.22, indicating that its share price is 322% more volatile than the S&P 500.

Earnings and Valuation

This table compares Masimo and NeurAxis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$2.05 billion	4.69	$81.50 million	$1.45	123.80
NeurAxis	$2.46 million	6.92	-$14.63 million	($1.84)	-1.29

Masimo has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Masimo and NeurAxis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0	1	5	0	2.83
NeurAxis	0	0	0	0	0.00

Masimo currently has a consensus price target of $191.40, indicating a potential upside of 6.62%. Given Masimo’s stronger consensus rating and higher possible upside, equities analysts clearly believe Masimo is more favorable than NeurAxis.

Insider & Institutional Ownership

86.0% of Masimo shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Masimo and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Masimo	3.85%	14.98%	6.95%
NeurAxis	-492.76%	N/A	-641.25%

Summary

Masimo beats NeurAxis on 11 of the 14 factors compared between the two stocks.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.